Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019
SAN DIEGO , Aug. 5, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
View HTML
Toggle Summary Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®
BeaconLBS now offers Biocept's Target Selector™ testing for liquid biopsy as part of its laboratory management network in the United States SAN DIEGO , July 22, 2019 /PRNewswire/ --  Biocept, Inc.  (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians
View HTML
Toggle Summary Biocept Announces Commercial Launch of Target Selector™ NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel
Biocept continues to expand its commercial offering for breast cancer and remains the only liquid biopsy provider to offer single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO , June 18, 2019 /PRNewswire/ -- Biocept, Inc.
View HTML
Toggle Summary Biocept to Present at the 9th Annual LD Micro Invitational Conference on June 4
SAN DIEGO , June 3, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally
Newly issued patent in China covers use of antibody cocktails in combination with a microchannel to capture rare cells such as circulating tumor cells (CTCs) from any biological sample of interest SAN DIEGO , May 28, 2019 /PRNewswire/ --  Biocept, Inc .
View HTML
Toggle Summary Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer
Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO , May 20, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed
View HTML
Toggle Summary Biocept Reports First Quarter 2019 Financial Results
- Revenues increased 27% compared to the first quarter of 2018 - Billable samples grew 7% year over year, and increased 23% vs. the fourth quarter of 2018 - Commercial gains driven primarily by broadened pathology partnership service - Conference call begins at 4:30 p.m.
View HTML
Toggle Summary Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019
SAN DIEGO , May 1, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve the outcomes of patients diagnosed with cancer, announces
View HTML
Toggle Summary Biocept Reports 2018 Fourth Quarter and Full Year Financial Results
Progress made implementing the Company's commercial strategy highlighted by 7% sequential quarterly growth in billable test volume in the fourth quarter of 2018 compared to the third quarter of 2018 Capitalized to deliver on key initiatives in 2019 including growth from pathology partnership and
View HTML
Toggle Summary Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment
Expansion of Biocept's EmpowerTC™ offering now includes predictive and prognostic biomarker testing to aid pathologists and urologists in the management of patients diagnosed with prostate cancer SAN DIEGO , March 26, 2019 /PRNewswire/ --  Biocept, Inc.
View HTML